Drug Trial Radar · NCT07540988
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
466
Planned (sponsor's estimate)
Start
Sep 17, 2026
Primary completion
Dec 5, 2028
Study completion Dec 12, 2028
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Apr 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). People can join the study if they have been diagnosed with this condition within the last 3 years and are at risk of developing progressive pulmonary fibrosis (PPF). The purpose of this study is to find out whether a medicine called nerandomilast helps people with fibrosing interstitial lung disease who may be at risk for their disease getting worse. Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets, and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Nerandomilast is a type of medicine that may help reduce lung function decline and slow disease progression. Participants are in the study for up to about 2 years and 4 months. During this time, they visit the study site regularly. Doctors regularly test lung function using methods like spirometry to measure forced vital capacity (FVC, maximum amount of air a participant can blow out after taking a deep breath) and DLCO (diffusing capacity of the lungs for carbon monoxide; it estimates how well oxygen moves from the lungs into the blood). Additionally, high-resolution computed tomography (HRCT) is performed to monitor how the lung condition is changing over time. The results are compared between the groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Interstitial Lung Diseases
Interventions
NerandomilastDrug
Nerandomilast
Placebo matching nerandomilastDrug
Placebo matching nerandomilast
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute change from baseline in forced vital capacity (FVC) (mL) at Week 52Time frame: at baseline, at week 52
Locations
162 sites in 20 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Not yet recruiting
University of Southern California
Los Angeles, California · Not yet recruiting
Newport Native MD, Inc
Newport Beach, California · Not yet recruiting
Yale University School of Medicine
New Haven, Connecticut · Not yet recruiting
Clinical Research Specialists LLC - Kissimmee
Kissimmee, Florida · Not yet recruiting
Lakeland Regional Medical Center - Lakeland
Lakeland, Florida · Not yet recruiting
Advanced Pulmonary Research Institute
Loxahatchee Groves, Florida · Not yet recruiting
Essence MD Research
Naples, Florida · Not yet recruiting
Avanza Medical Research Center
Pensacola, Florida · Not yet recruiting
Coastal Pulmonary & Critical Care
St. Petersburg, Florida · Not yet recruiting
Cleveland Clinic Florida
Weston, Florida · Not yet recruiting
Indiana University Health Enterprise Clinical Research Operation
Indianapolis, Indiana · Not yet recruiting
University of Kansas Medical Center
Kansas City, Kansas · Not yet recruiting
University of Michigan
Ann Arbor, Michigan · Not yet recruiting
University of Minnesota
Minneapolis, Minnesota · Not yet recruiting
Mayo Clinic, Rochester
Rochester, Minnesota · Not yet recruiting
Henderson Clinical Trials
Henderson, Nevada · Not yet recruiting
Weill Cornell Medicine-New York-60569
New York, New York · Not yet recruiting
New York Presbyterian Hospital -Columbia University
New York, New York · Not yet recruiting
Coastal Carolina Health Care, P.A. Pulmonary and Sleep Medicine
New Bern, North Carolina · Not yet recruiting
Southeastern Research Center-Winston-Salem-61365
Winston-Salem, North Carolina · Not yet recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Not yet recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Not yet recruiting
Temple University
Philadelphia, Pennsylvania · Not yet recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Not yet recruiting
Lowcountry Lung and Critical Care
Charleston, South Carolina · Not yet recruiting
Baylor University Medical Center
Dallas, Texas · Not yet recruiting
Metroplex Pulmonary & Sleep Center
McKinney, Texas · Not yet recruiting
UT Health San Antonio
San Antonio, Texas · Not yet recruiting
University of Utah Health Sciences Center
Salt Lake City, Utah · Not yet recruiting
Instituto de Medicina Respiratoria (IMeR)
Alberdi Sur, Argentina · Not yet recruiting
Fundacion NIBA Neurologia Infantil Buenos Aires
CABA, Argentina · Not yet recruiting
Consultorios Medicos del Buen Ayre
Capital Federal, Argentina · Not yet recruiting
Hospital Aleman
Capital Federal, Argentina · Not yet recruiting
Instituto Ave Pulmo - Fundacion Enfisema
Mar del Plata, Argentina · Not yet recruiting
INSARES
Mendoza, Argentina · Not yet recruiting
Fundacion Innovaciencia
Rosario, Argentina · Not yet recruiting
Royal Prince Alfred Hospital
Camperdown, Sydney, New South Wales, Australia · Not yet recruiting
Lung Research Queensland
Chermside, Queensland, Australia · Recruiting
Fiona Stanley Hospital
Murdoch, Western Australia, Australia · Not yet recruiting
Showing 40 of 162 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.